Search

Displaying results 2441 - 2450 of 10000 in total
  1. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. … Pharmacologically, it is a post-ganglionic parasympathetic inhibitor.

  2. Drug

    Secnidazole

    go.drugbank.com/drugs/DB12834
    ApprovedInvestigational

    [A245503] Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. … It is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class

  3. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] … [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA

  4. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  5. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    is used primarily in the treatment of endometriosis. … Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America.

  6. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    Tilactase is a beta-D-galactosidase obtained from _Aspergillus oryzae_. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. … [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338]

  7. Drug

    Floxuridine

    go.drugbank.com/drugs/DB00322
    ApprovedInvestigational

    It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. … When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate.

  8. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.

  9. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in the absence of MAPK signaling.

    Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
  10. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]